Diamyd's warrant is listed for trading on First North
Diamyd Medical AB (publ.) executed a direct placement on April 18th 2008, where
each issued new share was accompanied by a one year warrant with a subscription
price of SEK 100. These warrants will now be listed on the market place First
North.
In connection with this, Mangold Fondkommission AB assumes the role of liquidity
provider for the Diamyd Medical B share as well as the warrant. In order to be
able to act as liquidity provider, Mangold will borrow 4000 B shares from Diamyd
Medical's Chairman Anders Essen-Möller. The first day of trading with the
warrant on First North is expected to be June 10, 2008.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB,
elisabeth.lindner@diamyd.com
Phone: +46-8-661 00 26
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB,
sonja.catani@diamyd.com
Phone: +46-8-661 00 26
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. VATno: SE556530-142001.
This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and for which Phase III trials have been initiated in both the US and
Europe. Furthermore the company has initiated clinical studies within chronic
pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has
also out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com.
